135 Integration of T-cell activation and tumor mutation burden predicts anti-PD-1 response

• Matthew Adamow,
• Katherine S Panageas,
• Michael Postow,
• Margaret K Callahan,
• James W Smithy,
• Ronglai Shen,
• Fiona Ehrich,
• Colleen Maher,
• Jasme Lee,
• Xiyu Peng,
• Samuel A Funt,
• Niamh Keegan

Affiliations

Matthew Adamow

2Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA

Katherine S Panageas

1Memorial Sloan Kettering Cancer Center, New York, NY, USA

Michael Postow

1Memorial Sloan Kettering Cancer Center, New York, NY, USA

Margaret K Callahan

1Memorial Sloan Kettering Cancer Center, New York, NY, USA

James W Smithy

1Memorial Sloan Kettering Cancer Center, New York, NY, USA

Ronglai Shen

1Memorial Sloan Kettering Cancer Center, New York, NY, USA

Fiona Ehrich

1Memorial Sloan Kettering Cancer Center, New York, NY, USA

Colleen Maher

1Memorial Sloan Kettering Cancer Center, New York, NY, USA

Jasme Lee

1Memorial Sloan Kettering Cancer Center, New York, NY, USA

Xiyu Peng

1Memorial Sloan Kettering Cancer Center, New York, NY, USA

Samuel A Funt

1Memorial Sloan Kettering Cancer Center, New York, NY, USA

Niamh Keegan

1Memorial Sloan Kettering Cancer Center, New York, NY, USA